Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1075 of 2228 entries
View as:

This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated

Phase: N/A Priority: Normal
NCT ID: NCT03315936 Org: User:
Start: 11/02/17 End: 09/10/18 Due: 09/10/19

A Study to Test How Well Men Tolerate Different Doses of BI 3006337

Phase: N/A Priority: Normal
NCT ID: NCT05076422 Org: User:
Start: 10/18/21 End: 03/03/23 Due: 03/03/24

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Phase: N/A Priority: Normal
NCT ID: NCT03230097 Org: User:
Start: 09/29/17 End: 04/07/21 Due: 04/07/22

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Phase: N/A Priority: Normal
NCT ID: NCT03351244 Org: User:
Start: 12/07/17 End: 03/31/21 Due: 03/31/22

Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life

Phase: N/A Priority: Normal
NCT ID: NCT00539461 Org: User:
Start: 02/28/07 End: - Due: -

Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort

Phase: N/A Priority: Normal
NCT ID: NCT02242305 Org: User:
Start: 11/01/08 End: 07/20/09 Due: 07/20/10

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Phase: N/A Priority: Normal
NCT ID: NCT04927858 Org: User:
Start: 04/02/18 End: 11/15/18 Due: 11/15/19

Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02184312 Org: User:
Start: 04/30/08 End: - Due: -

A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.

Phase: N/A Priority: Normal
NCT ID: NCT03854552 Org: User:
Start: 03/15/19 End: 08/07/19 Due: 08/07/20

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Phase: N/A Priority: Normal
NCT ID: NCT00656136 Org: User:
Start: 04/30/08 End: 10/31/13 Due: 10/31/14

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02263976 Org: User:
Start: 08/31/03 End: - Due: -

Reversal Dabigatran Anticoagulant Effect With Idarucizumab

Phase: N/A Priority: Normal
NCT ID: NCT02815670 Org: User:
Start: 09/07/16 End: 10/19/19 Due: 10/19/20

Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use

Phase: N/A Priority: Normal
NCT ID: NCT02129192 Org: User:
Start: 05/31/14 End: 09/30/14 Due: 09/30/15

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT01951846 Org: User:
Start: 11/30/02 End: - Due: -

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

Phase: N/A Priority: Normal
NCT ID: NCT04894474 Org: User:
Start: 06/17/21 End: 07/24/22 Due: 07/24/23

To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03004404 Org: User:
Start: 01/12/17 End: 08/15/17 Due: 08/15/18

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Phase: N/A Priority: Normal
NCT ID: NCT01040130 Org: User:
Start: 01/31/10 End: - Due: -

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

Phase: N/A Priority: Normal
NCT ID: NCT00144339 Org: User:
Start: 12/31/02 End: - Due: -

Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients

Phase: N/A Priority: Normal
NCT ID: NCT02242279 Org: User:
Start: 06/30/04 End: - Due: -

Quality of Life and Changes in Metabolism of Lipids and Glucose After Switching to a Nevirapine-based Regimen in HIV+ Patients

Phase: N/A Priority: Normal
NCT ID: NCT00274001 Org: User:
Start: 09/30/01 End: 03/31/04 Due: 03/31/05

A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)

Phase: N/A Priority: Normal
NCT ID: NCT02242396 Org: User:
Start: 08/31/05 End: - Due: -

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01121406 Org: User:
Start: 04/30/10 End: 06/30/14 Due: 06/30/15

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01164501 Org: User:
Start: 07/31/10 End: 07/31/12 Due: 07/31/13

Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02254083 Org: User:
Start: 02/28/03 End: - Due: -

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02183467 Org: User:
Start: 01/31/08 End: - Due: -